score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Guideline			Copy Number	CDK4	Amplification				0.0	0.0		Putatively Actionable	Palbociclib	CDK4/6 inhibition	Targeted therapy	CDK4 amplification is characteristic of well-differentiated and dedifferentiated liposarcomas. Palbociclib shows activity in this context.	National Comprehensive Cancer Network. Soft Tissue Sarcoma NCCN Evidence Blocks (Version 1.2021). Accessed November 19th, 2019.	https://www.nccn.org/professionals/physician_gls/pdf/sarcoma_blocks.pdf													0				CDK4 Amplification	1.0	Osteosarcoma-OBM067	OBM067_T	
Putatively Actionable	Preclinical			Copy Number	MDM2	Amplification				0.0	0.0		Putatively Actionable	nutlin-3	MDM2-p53 inhibition	Targeted therapy	Presence of amplified MDM2 may suggest sensitivity to nutlin-3 in the absense of mutant TP53.	Endo S, Yamato K, Hirai S, et al. Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells. Cancer Sci. 2011;102(3):605-13.	https://doi.org/10.1111/j.1349-7006.2010.01821.x													0				MDM2 Amplification	0.0	Osteosarcoma-OBM067	OBM067_T	
Investigate Actionability		Clinical evidence		Somatic Variant	BCR	Missense	p.E555K	0.0894	123.0	0.0	0.0									Investigate Actionability	Imatinib	BCR-ABL inhibition	Targeted therapy	Secondary mutations in BCR-ABL may suggest resistance to imatinib in CML.	Soverini S, Hochhaus A, Nicolini FE, Gruber F, Lange T, Saglio G, et al. (2011) Bcr-Abl kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inihibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood: blood-2010-2012-326405	https://doi.org/10.1182/blood-2010-12-326405						0	0.0	0.0	0.0	BCR p.E555K (Missense)		Osteosarcoma-OBM067	Osteosarcoma-OBM067-Tumor-SM-2RCBH	Osteosarcoma-OBM067-Normal-SM-2RCCW
Biologically Relevant				Rearrangement	CDK4	Fusion	RAP1B--CDK4			0.0	0.0																					0				RAP1B--CDK4 Fusion		Osteosarcoma-OBM067		
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		Osteosarcoma-OBM067		
Biologically Relevant				Mutational Signature	COSMIC Signature 1	version 2	0.332																									0				COSMIC Signature (version 2) 1 (33%)		Osteosarcoma-OBM067		
Biologically Relevant				Mutational Signature	COSMIC Signature 13	version 2	0.223																									0				COSMIC Signature (version 2) 13 (22%)		Osteosarcoma-OBM067		
